Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

22 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
From decision to reflection: understanding the experiences and unmet care needs of patients treated with immunotherapy for melanoma in the adjuvant or metastatic setting.
Kamminga NCW, van der Veldt AAM, Wakkee M, van den Berge FR, van der Beek LAA, Joosen MCW, Joosse A, de Joode K, Nijsten TEC, Lugtenberg M. Kamminga NCW, et al. Among authors: de joode k. BMC Cancer. 2024 May 30;24(1):662. doi: 10.1186/s12885-024-12410-7. BMC Cancer. 2024. PMID: 38816701 Free PMC article.
Safe Stop IPI-NIVO trial: early discontinuation of nivolumab upon achieving a complete or partial response in patients with irresectable stage III or metastatic melanoma treated with first-line ipilimumab-nivolumab - study protocol.
Janssen JC, van Dijk B, de Joode K, Aarts MJB, van den Berkmortel FWPJ, Blank CU, Boers-Sonderen MJ, van den Eertwegh AJM, de Groot JWB, Jalving M, de Jonge MJA, Joosse A, Kapiteijn E, Kamphuis-Huismans AM, Naipal KAT, Piersma D, Rikhof B, Westgeest HM, Vreugdenhil G, Oomen-de Hoop E, Mulder EEAP, van der Veldt AAM. Janssen JC, et al. Among authors: de joode k. BMC Cancer. 2024 May 23;24(1):632. doi: 10.1186/s12885-024-12336-0. BMC Cancer. 2024. PMID: 38783238 Free PMC article.
Multi-omic analysis identifies hypoalbuminemia as independent biomarker of poor outcome upon PD-1 blockade in metastatic melanoma.
Leek LVM, Notohardjo JCL, de Joode K, Velker EL, Haanen JBAG, Suijkerbuijk KPM, Aarts MJB, de Groot JWB, Kapiteijn E, van den Berkmortel FWPJ, Westgeest HM, de Gruijl TD, Retel VP, Cuppen E, van der Veldt AAM, Labots M, Voest EE, van de Haar J, van den Eertwegh AJM. Leek LVM, et al. Among authors: de joode k. Sci Rep. 2024 May 16;14(1):11244. doi: 10.1038/s41598-024-61150-y. Sci Rep. 2024. PMID: 38755213 Free PMC article.
Effects of CTLA-4 Single Nucleotide Polymorphisms on Toxicity of Ipilimumab-Containing Regimens in Patients With Advanced Stage Melanoma.
de Joode K, Mora AR, van Schaik RHN, Zippelius A, van der Veldt A, Gerard CL, Läubli H, Michielin O, von Moos R, Joerger M, Levesque MP, Aeppli S, Mangana J, Mangas C, Trost N, Meyer S, Parvex SL, Mathijssen R, Metaxas Y. de Joode K, et al. J Immunother. 2024 Jun 1;47(5):190-194. doi: 10.1097/CJI.0000000000000506. Epub 2024 Feb 6. J Immunother. 2024. PMID: 38318726
The genomic and transcriptomic landscape of advanced renal cell cancer for individualized treatment strategies.
de Joode K, van de Geer WS, van Leenders GJLH, Hamberg P, Westgeest HM, Beeker A, Oosting SF, van Rooijen JM, Beerepoot LV, Labots M, Mathijssen RHJ, Lolkema MP, Cuppen E, Sleijfer S, van de Werken HJG, van der Veldt AAM. de Joode K, et al. Sci Rep. 2023 Jul 3;13(1):10720. doi: 10.1038/s41598-023-37764-z. Sci Rep. 2023. PMID: 37400554 Free PMC article.
The course of C-peptide levels in patients developing diabetes during anti-PD-1 therapy.
Basak EA, de Joode K, Uyl TJJ, van der Wal R, Schreurs MWJ, van den Berg SAA, Oomen-de Hoop E, van der Leest CH, Chaker L, Feelders RA, van der Veldt AAM, Joosse A, Koolen SLW, Aerts JGJV, Mathijssen RHJ, Bins S. Basak EA, et al. Among authors: de joode k. Biomed Pharmacother. 2022 Dec;156:113839. doi: 10.1016/j.biopha.2022.113839. Epub 2022 Oct 11. Biomed Pharmacother. 2022. PMID: 36228374 Free article.
Associations between patient and disease characteristics and severe adverse events during immune checkpoint inhibitor treatment: An observational study.
Basak EA, Vermeer NS, de Joode K, Hurkmans DP, Velthuis DEM, Oomen-de Hoop E, Schreurs MWJ, Bins S, Koolen SLW, Debets R, van der Veldt AAM, Aerts JGJV, Joosse A, Mathijssen RHJ. Basak EA, et al. Among authors: de joode k. Eur J Cancer. 2022 Oct;174:113-120. doi: 10.1016/j.ejca.2022.07.015. Epub 2022 Aug 19. Eur J Cancer. 2022. PMID: 35988409 Free article.
22 results